Urodynamix Technologies Ltd. Reports Fiscal 2009 Second Quarter Results

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today reported its financial
results for its fiscal second quarter ended June 30, 2009. The Company reported
revenues of $21,871, a 70% decrease over the same quarter of the prior year. The
Company's order backlog at June 30, 2009 was $92,576 compared to nil at the end
of the comparative quarter June 30, 2008.


The decrease in revenue resulted from not being able to finalize contracts with
new distributors for the uroNIRS 2000 initially targeted for completion during
the quarter. "Although the Company made significant progress in the expansion of
its worldwide distribution, the Company was not able to complete these new
agreements in the second quarter. The results for the quarter are below our
expectations and we have taken steps to get the sales of uroNIRS back on target
including changes in personnel and the re-alignment of duties. Notwithstanding
these results, customer and dealer feedback remains encouraging and new sales
activities are already showing results. Management is confident that the
expansion of its distribution channels can and will proceed as planned with this
new and enhanced sales infrastructure.


In addition to continued efforts to expand worldwide distribution and an
increased focus and resources for sales in the US market, we have also made
material reductions to our infrastructure costs, allowing us to reduce our net
cash burn. These cost reductions were implemented in all departments and at all
levels throughout the Company including a voluntary reduction in executive
compensation. We believe these activities will allow us to secure the necessary
short term financing to allow us to achieve our revenue and earnings targets.
The Company retains its confidence in the uroNIRS technology and remains
focussed on its successful worldwide launch," stated Barry Allen, President and
CEO of Urodynamix Technologies Ltd.


Gross margin at 66.1% of revenue increased from 51.8% of revenue for the
comparative quarter ended June 30, 2008. Expenses for the three months ended
June 30, 2009 were $877,498 compared to $893,858 for the comparative quarter of
the prior year, a decrease of $16,360. The increase in sales and marketing, to
support the introduction of the uroNIRS 2000 was offset by a decrease in
research and development expenses. Administrative expenses at $361,562 are
comparable to the same period of the prior year.


The net loss for the quarter ended June 30, 2009 was $909,934 or $0.01 per share
basic and diluted, as compared to a net loss of $846,400 or $0.01 per share
basic and diluted for the quarter ended June 30, 2008. The increase in the loss
was due to the decrease in sales in the quarter and a $47,018 foreign exchange
loss on revaluation of US dollar assets and liabilities at June 30, 2009.


As of June 30, 2009, the Company had cash and cash equivalents of $575,027, is a
decrease from $2,262,794 at December 31, 2008. Working capital at June 30, 2009
was $505,289 and the Company remains debt free. The Company has taken steps to
reduce its monthly cash burn to approximately $150,000 per month and management
is actively seeking new financing.


About Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd. is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic
hyperplasia, and traumatic increases in intra-abdominal pressure that cause
abdominal compartment syndrome. Urodynamix's breakthrough medical technology has
the potential to beneficially affect more than 200 million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.

Urodynamix Technologies Ltd. (TSXV:URO)
Graphique Historique de l'Action
De Juil 2024 à Août 2024